The Shifting Geography of Innovation in Endourology.

The geographic origin of endourological innovation is undergoing a fundamental and measurable transformation. This editorial maps a decisive shift across four domains: suction-integrated ureteroscopy and ureteral access sheaths (UASs), single-use flexible ureteroscopes, laser lithotripsy platforms, and robotic flexible ureteroscopy, using four independent indicators: Food and Drug Administration (FDA) regulatory clearances, international patent filings, citation impact, and guideline representation. The turning point for suction-enabled ureteroscopy was 2016, when Well Lead Medical (China) obtained the first FDA 510(k) clearance for a suction-capable UAS, with Chinese manufacturers subsequently dominating new approvals in this category. In single-use ureteroscopy, between 2022 and April 2026, Chinese manufacturers accounted for 47% of FDA 510(k) clearances, matching the USA in absolute count for the first time in the history of the field. In laser lithotripsy, China's share of annual patent filings grew from <10% to >35% between 2015 and 2024. In robotic flexible ureteroscopy, Asian manufacturers are now entering a field previously defined by European and Turkish platforms. Analysis of the EAU Urolithiasis Guidelines 2026 (n = 312 publications, from 2018) reveals that European publications have historically dominated citations (37.8%), followed by Asia (27.9%) and North America (19.2%); strikingly, Asian publications surpassed Europe in annual citation share by 2025, driven by a dramatic rise since 2023. For European and North American stakeholders, the appropriate response is not defensiveness but strategic engagement, through international collaboration, cross-border training, and institutional adaptability, in the shared interest of improving patient care worldwide.